Abstract
There is much interest in the potential use of Cox-2 selective inhibitors in combination with other cancer therapeutics. Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase- 2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis. Expression of Cox-2 enhances survival and proliferation of malignant cells, while negatively influencing anti-tumor immunity. Hematological malignancies expressing elevated levels of Cox-2 potentially avoid immune responses by producing factors that enhance angiogenesis and metastasis. Cellular immune responses regulated by natural killer cells, cytotoxic T lymphocytes, and T regulatory cells are also influenced by Cox-2 expression. Therefore, Cox-2 selective inhibitors have promising therapeutic potential in patients suffering from certain hematological malignancies.
Keywords: cyclooxygenase-2 (Cox-2), inflammation, hematological malignancies, chronic lymphocytic, leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, multiple myeloma, anti-tumor immunity, angiogenesis
Current Pharmaceutical Design
Title: Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Volume: 14 Issue: 21
Author(s): M. P. Bernard, S. Bancos, P. J. Sime and R. P. Phipps
Affiliation:
Keywords: cyclooxygenase-2 (Cox-2), inflammation, hematological malignancies, chronic lymphocytic, leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, multiple myeloma, anti-tumor immunity, angiogenesis
Abstract: There is much interest in the potential use of Cox-2 selective inhibitors in combination with other cancer therapeutics. Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase- 2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis. Expression of Cox-2 enhances survival and proliferation of malignant cells, while negatively influencing anti-tumor immunity. Hematological malignancies expressing elevated levels of Cox-2 potentially avoid immune responses by producing factors that enhance angiogenesis and metastasis. Cellular immune responses regulated by natural killer cells, cytotoxic T lymphocytes, and T regulatory cells are also influenced by Cox-2 expression. Therefore, Cox-2 selective inhibitors have promising therapeutic potential in patients suffering from certain hematological malignancies.
Export Options
About this article
Cite this article as:
Bernard P. M., Bancos S., Sime J. P. and Phipps P. R., Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise, Current Pharmaceutical Design 2008; 14 (21) . https://dx.doi.org/10.2174/138161208785294654
DOI https://dx.doi.org/10.2174/138161208785294654 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phospholipid Bilayer Nanodiscs: A Powerful Tool to Study the Structural Organization and Biochemical Reactivity of Proteins in Membrane-like Environments
Current Topics in Medicinal Chemistry Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma
Current Molecular Medicine Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets Diterpenoids from Liverworts and their Biological Activities
Current Organic Chemistry Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy
Current Drug Delivery Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Targeting the IL-6 Pathway in Multiple Myeloma and its Implications in Cancer-Associated Gene Hypermethylation
Medicinal Chemistry Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Retinoid Receptors in Inflammatory Responses: A Potential Target for Pharmacology
Current Drug Targets - Inflammation & Allergy Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters